Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 17576784.
- Also identified by PMC identifier 1955116.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The question of switching is not only a question of clinical practice, but has an important scientific dimension as well See linked article, p 893
Medical subject headings
- Antirheumatic Agents
- Tumor Necrosis Factor-alpha